Innovative Development of Reactor-Produced Radionuclides and Radiopharmaceuticals
Radionuclides and radiopharmaceuticals produced by reactors are important components and main material foundations of the nuclear healthcare industry.Therefore,summarizing the current status of reactor-produced radionuclides and radiopharmaceuticals is practically significant for accelerating the development of these products in China and promoting the construction of a self-reliant full-chain system.Through literature review,questionnaire survey,field research,and industry discussions,this study analyzes the supply and demand situation,current status,and trends of reactor-produced radionuclides and radiopharmaceuticals in China and abroad.Currently,China has achieved independent supply of a small number of reactor-produced radionuclides such as 131I,177Lu,and 89Sr;however,the production capacity of these radionuclides cannot meet domestic demand,and most commonly used radionuclides in clinical practice still rely on imports.Meanwhile,the current reactor-produced radiopharmaceuticals face bottlenecks such as a limited variety of drugs,insufficient research and development innovation,and limited production capacity,making it difficult to meet actual clinical needs.Therefore,the supply and diversification of reactor-produced radionuclides should be ensured considering the current status and trends of their supply and demand.It is necessary to promote the large-scale preparation of reactor-produced radionuclides based on clinical needs,support the development and application of more innovative radiopharmaceuticals,and further accelerate the formation of a self-reliant development system for the reactor-produced radionuclides and radiopharmaceuticals in China.Additionally,it is urgent to enrich development models and form innovative concepts,providing reliable support for the sustainable development of nuclear medicine in China.
reactormedical radionuclidesradiopharmaceuticalssupply and demand situationindependence
国家科技期刊平台
NSTL
万方数据
